1.185

6.69% -0.085

Regulus Therapeutics Inc (RGLS)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Regulus Therapeutics Inc stock is traded at $1.185, with a volume of 394.92K. It is down -6.69% in the last 24 hours and down -21.52% over the past month. Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Previous Close:

$1.27

Open:

$1.26

24h Volume:

394.92K

Relative Volume:

0.85

Market Cap:

$83.19M

Revenue:

Net Income/Loss:

$-30.04M

P/E Ratio:

-0.75

EPS:

-1.58

Net Cash Flow:

$-27.38M

1W Performance:

+18.50%

1M Performance:

-21.52%

6M Performance:

-18.84%

1Y Performance:

-13.82%

1-Day Range:

$1.15

$1.265

1-Week Range:

$1.01

$1.60

52-Week Range:

$0.8301

$3.79

Regulus Therapeutics Inc Stock (RGLS) Company Profile

Name

Regulus Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

858-202-6300

Address

4224 CAMPUS POINT COURT, SAN DIEGO, CA

Employee

Twitter

@regulusrx

Next Earnings Date

2024-11-07

Latest SEC Filings

RGLS's Discussions on Twitter

Compare RGLS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGLS Regulus Therapeutics Inc	1.185	83.19M	0	-30.04M	-27.38M	-1.58
VRTX Vertex Pharmaceuticals Inc	474.04	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.89	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.69	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.71	28.75B	3.30B	-501.07M	1.03B	-2.1146

Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-02-24	Initiated	Oppenheimer	Outperform
Mar-18-24	Initiated	Leerink Partners	Outperform
Mar-28-18	Initiated	B. Riley FBR, Inc.	Neutral
Jan-05-18	Initiated	Leerink Partners	Outperform
Jun-13-17	Reiterated	Chardan Capital Markets	Buy
Mar-06-17	Reiterated	Wedbush	Outperform
Jan-30-17	Downgrade	Needham	Buy → Hold
Jan-30-17	Downgrade	Wells Fargo	Outperform → Market Perform
Dec-07-16	Reiterated	Chardan Capital Markets	Buy
Nov-02-16	Reiterated	Needham	Buy
Jul-25-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	Chardan Capital Markets	Buy
Jun-28-16	Reiterated	FBR Capital	Outperform
Jun-28-16	Reiterated	Needham	Buy
Jun-07-16	Reiterated	Chardan Capital Markets	Buy
Apr-13-16	Initiated	Chardan Capital Markets	Buy
Dec-04-15	Initiated	Wells Fargo	Outperform
Jun-09-15	Initiated	Guggenheim	Buy
Apr-21-15	Resumed	FBR Capital	Outperform
Nov-24-14	Initiated	Deutsche Bank	Buy
Aug-07-14	Reiterated	FBR Capital	Outperform
Aug-14-13	Reiterated	Needham	Buy

View All

Regulus Therapeutics Inc Stock (RGLS) Latest News

Feb 05, 2025

Checking in on Regulus Therapeutics Inc (RGLS) after recent insiders movement - Knox Daily

Feb 05, 2025

Is Regulus Therapeutics Inc (NASDAQ: RGLS) Stock Worth Investing In for High Returns? - Marketing Sentinel

Feb 05, 2025

Feb 04, 2025

RGLS’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 04, 2025